(0.34%) 5 117.05 points
(0.33%) 38 365 points
(0.38%) 15 989 points
(-0.97%) $83.04
(5.36%) $2.03
(0.35%) $2 355.40
(0.49%) $27.67
(4.13%) $960.15
(-0.26%) $0.932
(-0.44%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 12.23%
@ $5.48
発行日: 15 2月 2024 @ 05:23
リターン: -20.73%
前回のシグナル: 2月 15 - 02:19
前回のシグナル:
リターン: 1.96 %
Live Chart Being Loaded With Signals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema...
Stats | |
---|---|
本日の出来高 | 1.21M |
平均出来高 | 3.18M |
時価総額 | 894.69M |
EPS | $0 ( 2024-02-26 ) |
次の収益日 | ( $-0.220 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.68 |
ATR14 | $0.0120 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Thackray Helen M. | Sell | 7 525 | Common Stock |
2024-02-29 | Milano Vincent | Buy | 999 | Common Stock |
2024-02-29 | Heggie Theresa | Buy | 999 | Common Stock |
2024-01-03 | Stonehouse Jon P | Sell | 20 000 | Common Stock |
2024-01-03 | Stonehouse Jon P | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
75.11 |
Last 100 transactions |
Buy: 4 343 991 | Sell: 822 588 |
ボリューム 相関
BioCryst Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
GXII | -0.959 |
MLTX | -0.944 |
NCAC | -0.944 |
LMNR | -0.944 |
VPCB | -0.943 |
TETC | -0.941 |
LMRKO | -0.939 |
PPYAU | -0.938 |
FTPA | -0.937 |
CRZN | -0.936 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
BioCryst Pharmaceuticals 相関 - 通貨/商品
BioCryst Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $331.41M |
総利益: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2023 |
収益: | $331.41M |
総利益: | $325.10M (98.09 %) |
EPS: | $-1.180 |
FY | 2022 |
収益: | $270.83M |
総利益: | $264.23M (97.57 %) |
EPS: | $-1.330 |
FY | 2021 |
収益: | $157.17M |
総利益: | $149.91M (95.38 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。